Oncoinvent presents 3Q company update in live webcast
Oslo, Norway, 28 October 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is hosting a live webcast at 10:00 AM CET today, Wednesday, 28 October 2026.
- Presenters: CEO Øystein Soug, CFO Ramzi Amri, CMO Zuzana Jirakova Trnkova - Time: 10:00am CET - Webcast link: https://qcnl.tv/p/8awn9AmyNjOd67OuY7TwRQ
Highlights:
- Recruited 16 patients into the ovarian Phase 2 trial, having a total of 71 patients by end 3Q - Added one more clinical site to Oncoinvent's Phase 2 trial; 11 clinical sites now recruiting - Published Normal tissue dosimetry results in Journal of Nuclear Medicine - Presented three abstracts at EANM and ESMO - Completed successful private placement raising gross proceeds of NOK 148.5 million - Appointed Dr Zuzana Jirakova Trnkova as Chief Medical Offier
The presentation material and the recording of the webcast will be made available at www.oncoinvent.com.
Oncoinvent reports its financial results on a half-yearly basis, complemented by quarterly business updates to keep stakeholders informed and ensure ongoing transparency.
For further information, please contact: Oncoinvent Oystein Soug, Chief Executive Officer IR@oncoinvent.com
Optimum Strategic Communications Zoe Bolt, Katherine Bliss, Henry Williams +44 (0) 203 882 9621 oncoinvent@optimumcomms.com
About Oncoinvent
Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent's product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2H2026 (safety) and 1H2027 (early efficacy). With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).